semaj83/ctmatch_classification huggingface dataset:
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Congenital Heart Disease Male or Female over 18 years of age Moderate or Complex Congenital Heart Disease Willingness to Consent  Pregnancy Surgery within 6 months Unrepaired cyanotic heart disease Patients with Eisenmenger Syndrome physiology
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intermittent Claudication Peripheral Vascular Disease All ethnic groups, male or female above the age of 18 years Diagnosis of mild intermittent claudication Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device Blood pressure currently under moderate control (< 160/100mmHg) No current foot ulceration  Patients meeting any of the following are to be excluded Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol Has diabetes Ankle Brachial Pressure Index > 0.9 Has any metal implants Pregnant Has a cardiac pacemaker or defibrillator device Has recent lower limb injury or lower back pain Has current foot ulceration or other skin ulcers Has foot deformities
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Remote Ischaemic Preconditioning Contrast Induced Nephropathy Elective intra-arterial peripheral angiography/angioplasty Patients >21 years of age Patients with CKD as evidenced by eGFR levels of 30ml/min < eGFR < 60ml/min (moderate risk) or eGFR levels of >= 60ml/min (low risk)  Severe renal impairment eGFR <30ml/min Evidence of acute renal failure or patients on dialysis History of previous CIN Contraindication to volume replacement therapy Pregnancy Patients on glibenclamide or nicorandil (these medications may interfere with RIPC)
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 4.0-12.0,  Obsessive-Compulsive Disorder OCD Participants (N = 72) Aged 4-12 years and living within a four-hour commute from NIH Currently meet DSM-IV for OCD Recent onset of symptoms (less than 6 months.) Healthy Controls (N = 60-72) Age and sex matched to ODC participants Must be free of current or past psychopathology  OCD Participants Diagnosis of schizophrenia, schizoaffective, bipolar, delusional, or psychotic disorder; autistic spectrum disorder or pervasive developmental disorder; neurologic disorder other than tics; or rheumatic fever Significant or unstable medical illness Full scale IQ less than 80 Healthy Controls Full scale IQ less than 80 Significant or unstable medical illness
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Coronary Arteriosclerosis Adults older than 21 years Coronary artery disease established by angiography No myocardial infarction within 1 month Left ventricular ejection fraction greater than 30% No congestive heart failure symptoms within 2 months No medical condition that might prohibit safe participation in cardiac rehabilitation Subject understands protocol and provides written, informed consent in addition to willingness to comply with specified follow-up evaluations  Significant structural heart disease (e.g. hypertrophic or dilated cardiomyopathy, valvular heart disease) as determined by echocardiography Angina pectoris that is prolonged in duration (greater than 20 minutes), or does not respond to nitroglycerin (2 tablets) Subject physically unable to perform cardiac rehabilitation protocol due to neurologic or orthopedic conditions Hypersensitivity to organic nitrates Women of childbearing age unless recent pregnancy test is negative Lactating women Known hypersensitivity to dipyridamole or to gadolinium if patient eligible for MRI study
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.5-12.0,  Pharyngitis Give informed consent, assent, and documentation of patient authorization for disclosure of study results Since all patients are below the legal age of consent, assent from the patient must be obtained (as applicable following state regulations) and written informed consent obtained from the parent or legal guardian Age > = 6 months -12 years A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the clinical signs and symptoms compatible with tonsillitis and/or pharyngitis, including sore throat or difficulty feeding or swallowing or irritability that suggests the presence of a sore throat with at least one of the following Tonsillar or pharyngeal exudate Tender cervical lymph nodes Fever or history of fever treated with antipyretics Odynophagia Uvular edema Pharyngeal Erythema of moderate or greater intensity  Chronic or recurrent (two weeks duration two times per year) odynophagia or enlarged tonsils secondary to viral or proven bacterial etiology The need for hospitalization or I.V. antimicrobial therapy Pharyngitis known or suspected to be due to a pathogen resistant to beta-lactam antimicrobials Patients who are known carriers of S. pyogenes Previous allergy, serious adverse reaction to, or intolerance to, penicillin or any other member of the beta-lactam class of antimicrobials Any serious illness or concomitant condition that the investigator judges would preclude the study evaluations or make it unlikely that the course of study therapy and follow-up could be completed. This would also Any rapidly progressive underlying disease with a shortened life expectancy The inability to swallow the study dosage form Unable to understand the requirements of the study Neutropenia (<1000 PMNs/mm3) or other known immunocompromised state
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 4.0-16.0,  Kawasaki Disease Males or females between 4 and 16 Meet the epidemiological definition of Kawasaki Disease or have a diagnosis of incomplete KD, including evidence of coronary artery disease as determined by their physician Be able to exercise adequately to achieve 85% age predicted maximum heart rate  Terminal illness where expected survival is < 6 months
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 5.0-16.0,  Learning Disorders Child Behavior Disorders DSM-IV Axis II diagnosis of mental retardation behavioural and family therapy tried for 6 months but has failed in school, at least part time score of >=8 on hostility scale subject is otherwise healthy  Patients with a seizure disorder requiring repeated change of medication extrapyramidal symptoms not well controlled by medication abnormal and clinically significant electrocardiogram (ECG) changes history of tardive dyskinesia (a condition of uncontrollable movements of the tongue, lips, face, trunk, hands and feet that is seen in patients receiving long-term medication with certain types of antipsychotic drugs), or neuroleptic malignant syndrome (a rare condition in patients receiving antipsychotic medication in which patients may develop fever, sweating, unstable blood pressure, rigid muscles, and other symptoms, including changes in their normal mental state) known hypersensitivity to antipsychotic medications, including risperidone
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 8.0-25.0,  Kawasaki Disease History of Kawasaki disease more than 12 months before enrollment Present age of 8 years or older  Diabetes mellitus Not controlled hypertension Treatment with drugs thay modify endothelial function such as angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers Smokers of more than 5 cigarettes per day Total cholesterol higher than 250 mg/dl Triglycerides higher than 300mg/dl Chronic treatment with statins Chronic renal insufficiency (creatinine > 1.5 mg/dl)
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-90.0,  Burn Ages 0-90 years Any patient admitted to the hospital with burn injury requiring grafting and a donor site  Patient with severe burn injuries expected to die
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Allergic Rhinitis Ability to understand and provide informed consent Male or Female (non-pregnant), age 18-50 Females must be: Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral tubal ligation), OR postmenopausal (at least 1 year since last menses), OR using a medically acceptable form of birth control throughout the duration of the study Clinical history of seasonal or perennial allergic rhinitis for at least two years, with or without mild persistent asthma Positive puncture skin test greater than or equal to 5 mm diluent control Positive CAP-RAST to Fel d 1 > 0.35 kU/L Positive intranasal cat allergen challenge as defined by > 5 sneezes or a tripling of measured nasal lavage mediators In vitro assay of basophil responsiveness to cat allergen with greater than 20% histamine release The use of antihistamines, cromolyns, leukotriene modifiers and other non-steroid (astelin and topical decongestants), nasal medications will be allowed, but they will be withheld for 5 days prior to each nasal allergen provocation session. Inhaled corticosteroids for mild asthma will be permissible No known contraindications to therapy with omalizumab  Asthma with FEV1 < 80%, moderate to severe asthma classification per NAEP Standards (1997 National Asthma Education and Prevention Program Expert Panel Report II guidelines) Serum IgE levels less than 30 IU/mL or greater than 700 IU/mL at the time of enrollment will be excluded Unexplained elevation of ESR, hematocrit < 32%, WBC count 2400/microliter lower limit of normal, platelet < 75000/microliter, creatinine > 141.4 micromolar/L, or AST > 100 IU/L Body weight less than 30 kg or greater than 150 kg will be excluded Plans to become pregnant or breastfeed will be excluded from the study A perforated nasal septum, structural nasal defect, large nasal polyps causing obstruction, evidence of acute or chronic sinusitis A life expectancy less than 6 months A terminal illness as determined by the investigator A history of malignancy, anaphylaxis or bleeding disorder are also illnesses Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 2.0-12.0,  Tonsillitis Patients who had evidence of acute pharyngitis/tonsillitis based on erythematous pharyngeal mucosa or thick exudate covering the pharynx and tonsillar area, and at least one of the following signs or symptoms were included: sore/scratchy throat; pain on swallowing; chills and/or fever cervical adenopathy; scarlet fever rash on the face and skin folds, or red tongue with prominent papillae ("strawberry tongue"). Subjects were required to have a positive rapid antigen detection test (RADT) or a positive culture of the pharynx or tonsils for GABHS  Patients were excluded if they had previously diagnosed disease(s) of immune function or treatment with any systemic antibiotic within the previous 7 days
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) and in accordance with local guidelines Patients eligible to anti-TNF therapy Patients naïve to anti-TNFa drugs Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form  Patients with tumors Patients already included in clinical trials
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.167-20.0,  Mucocutaneous Lymph Node Syndrome Kawasaki Disease Male Age 2 months to 20 years of age Female Age 2 months to 11 years of age Provision of Parental Consent Kawasaki Disease Presentation  Laboratory Any laboratory toxicity, at the time of the screening visit or at any time during the study that in the opinion of the Investigator would preclude participation in the study or Platelet count < 100,000/mm3 WBC count < 3,000 cells/mm3 Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal for the Lab Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit Female subjects diagnosed with KD 12 years of age and older Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept Prior or concurrent cyclophosphamide therapy Prior treatment with any TNF alpha antagonist or steroid within 48 hours prior to initiation of IVIG Concurrent sulfasalazine therapy